In a recent letter to the editor of Leukemia, Abdelhaleem et al.
suggested that the fusion of CALM (clathrin-assembly protein- Letters to the Editor like lymphoid-myeloid, also known as PICALM) and AF10 (also known as MLLT10) genes is common in acute megakaryoblastic leukemia (AMKL) in children without Down's syndrome (DS), which was based on the observation of two cases of non-DS AMKL with a chromosomal translocation t(10;11)(p13;q14-21) that resulted in a CALM-AF10 fusion.
1 Interestingly, the 11q14-21 region had previously been identified as a cluster of uncommon breakpoints in AMKL (1), but the CALM-AF10 translocation could not be detected by conventional cytogenetics in two larger series that included up to 72 patients with AMKL. 2, 3 However, the fact that we had identified a subgroup of non-DS AMKL cases with marked increase of HOXA cluster gene expression, which was reminiscent of the HOXA cluster gene expression profiles reported in CALM-AF10 positive T-cell acute lymphoblastic leukemias (T-ALLs), 4 ,5 prompted us to search for cryptic CALM-AF10 translocations in non-DS AMKL.
To identify such cryptic CALM-AF10 fusion products, we screened 22 samples that were included in our previous study 3 from which RNA was available using an established reversetranscription PCR (RT-PCR) protocol. 6 The presence of specific CALM-AF10 fusion transcripts in the cell line U937 and in four T-ALL samples with a known t(10;11)(p13;q14-21) translocation was detected (Figure 1 ). The breakpoint between CALM and AF10 was verified by sequencing. We did not detect any CALM-AF10 fusion transcripts in non-DS AMKL samples. Taken together, previously reported cytogenetic data and our results suggest that CALM-AF10 translocations represent rare events in AMKL.
These authors chose not to respond to Dr Greiner et al.
Characterization of graft-versus-leukemia responses in patients treated for advanced chronic lymphocytic leukemia with donor lymphocyte infusions after in vitro T-cell depleted allogeneic stem cell transplantation following reduced-intensity conditioning Patients with chronic lymphocytic leukemia (CLL) unresponsive to fludarabine-based chemotherapy have a poor prognosis. For these patients allogeneic stem cell transplantation (alloSCT) may be a potential curative treatment modality. Several reports have shown that alloSCT following reduced-intensity conditioning (RIC) significantly diminished treatment-related mortality (TRM) while preserving the graft-versus-leukemia (GvL) effect. However, considerable toxicity due to a high incidence of acute graftversus-host disease (GvHD) and extensive chronic GvHD was observed. 1,2 The use of alemtuzumab (anti-CD52) to deplete for donor and recipient T cells as part of the RIC strategy effectively reduces GvHD, while the administration of alemtuzumab with the stem cell graft may also result in a profound anti-CLL effect. Once durable donor engraftment is achieved, adoptive immunotherapy with donor lymphocyte infusion (DLI) can be applied to promote and enhance the GvL effect. 3, 4 We have demonstrated the feasibility of this approach and showed a reduction in both the incidence and the severity of GvHD. 5 Here, we report the result of 12 patients with advanced CLL treated with in vitro T-cell-depleted RIC alloSCT followed by postponed administration of DLI. Patients with progressive CLL after conventional chemotherapy with ages between 18 and 70 years with a human leukocyte antigen (HLA)-identical sibling donor or an HLA-compatible matched unrelated donor (MUD) were eligible for this study. Patient and transplantation characteristics of the 12 enrolled patients are summarized in Table 1 . The conditioning regimen consisted of fludarabine 30 mg/m 2 /day i.v. on days À10 to À6, busulfan 3.2 mg/kg/day i.v. on days À6 and À5 and antithymocyte globulin 10 mg/kg/ day i.v. on days À4 to À1. T-cell depletion of the stem cell product was performed by incubation with 20 mg alemtuzumab for 30 min. No post-transplant GvHD prophylaxis was administered. DLI was anticipated to be administered in all patients. Patients with persistent disease or incomplete donor chimerism at 6 months after alloSCT received 5 Â 10 6 CD3 þ cells/kg. Escalating doses of CD3 þ T cells were administered at 3-6 months intervals in the absence of development of GvHD if mixed chimerism or CLL persisted. The median follow-up was 21 months (range, 7-61 months). Disease response was assessed using National Cancer Institute Working Group (NCI-WG) criteria with the following additions. Complete response (CR) or partial response (PR) required complete or at least 50% clearance of CLL cells from both bone marrow (BM) and peripheral blood (PB) as detected by multicolor flow cytometry
